Pathogenese, Klinik und aktuelle Therapie der Rosazea

详细信息    查看全文

• 作者：Dr. L.I. Gonser ; Dr. C.E. Gonser ; Prof. Dr. M. Schaller
• 关键词：Demodex ; Erythematotelangiectatic rosacea ; Papulopustular rosacea ; Phymatous rosacea ; Ocular rosacea
• 刊名：Der Hautarzt
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：67
• 期：1
• 页码：69-84
• 全文大小：3,631 KB
• 参考文献：1.Gauwerky K, Klovekorn W, Korting HC et al (2009) Rosacea. J Dtsch Dermatol Ges 7:996–1003PubMed
  2.Steinhoff M, Buddenkotte J, Aubert J et al (2011) Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 15:2–11CrossRef PubMed PubMedCentral
  3.Yamasaki K, Gallo RL (2009) The molecular pathology of rosacea. J Dermatol Sci 55:77–81CrossRef PubMed PubMedCentral
  4.Schauber J, Gallo RL (2009) Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 124:R13–R18CrossRef PubMed
  5.Yamasaki K, Schauber J, Coda A et al (2006) Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20:2068–2080CrossRef PubMed
  6.Yamasaki K, Di Nardo A, Bardan A et al (2007) Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13:975–980CrossRef PubMed
  7.Yamasaki K, Kanada K, Macleod DT et al (2011) TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 131:688–697CrossRef PubMed PubMedCentral
  8.Sattler EC, Maier T, Hoffmann VS et al (2012) Noninvasive in vivo detection and quantification of Demodex mites by confocal laser scanning microscopy. Br J Dermatol 167:1042–1047CrossRef PubMed
  9.Chen W, Plewig G (2014) Human demodicosis: revisit and a proposed classification. Br J Dermatol 170:1219–1225CrossRef PubMed
  10.Kulka M, Sheen CH, Tancowny BP et al (2008) Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398–410CrossRef PubMed PubMedCentral
  11.Schwab VD, Sulk M, Seeliger S et al (2011) Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 15:53–62CrossRef PubMed PubMedCentral
  12.Lehmann P (2005) [Rosacea. Clinical features, pathogenesis and therapy]. Hautarzt 56:871–885. (quiz 886–887)CrossRef PubMed
  13.Wilkin J, Dahl M, Detmar M et al (2002) Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 46:584–587CrossRef PubMed
  14.Melnik BJT (2012) Akne und Rosazea. In: Plewig G Landthaler M, Burgdorf W, Hertl M, Ruzicka T (Hrsg) Braun-Falco’s Dermatologie, Venerologie und Allergologie. Springer, Berlin, S 1218–1225
  15.Spoendlin J, Voegel JJ, Jick SS et al (2012) A study on the epidemiology of rosacea in the U.K. Br J Dermatol 167:598–605CrossRef PubMed
  16.Reinholz M, Tietze JK, Kilian K et al (2013) Rosacea – S1 guideline. J Dtsch Dermatol Ges 11(768–780):768–779PubMed
  17.Drolet B, Paller AS (1992) Childhood rosacea. Pediatr Dermatol 9:22–26CrossRef PubMed
  18.Chamaillard M, Mortemousque B, Boralevi F et al (2008) Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 144:167–171CrossRef PubMed
  19.Seite S, Benech F, Berdah S et al (2013) Management of rosacea-prone skin: evaluation of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay Thermal spring water as monotherapy or adjunctive therapy. J Drugs Dermatol 12:920–924PubMed
  20.Liste R (2015)
  21.Van Zuuren EJ, Kramer SF, Carter BR et al (2011) Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol 165:760–781CrossRef PubMed
  22.Fowler J, Jarratt M, Moore A et al (2012) Once-daily topical brimonidine tartrate gel 0.5 % is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 166:633–641CrossRef PubMed PubMedCentral
  23.Moore A, Kempers S, Murakawa G et al (2014) Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 13:56–61PubMed
  24.Allen KJ, Davis CL, Billings SD et al (2007) Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis 80:149–151PubMed
  25.Forton F, Seys B, Marchal JL et al (1998) Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy. Br J Dermatol 138:461–466CrossRef PubMed
  26.Kocak M, Yagli S, Vahapoglu G et al (2002) Permethrin 5 % cream versus metronidazole 0.75 % gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 205:265–270CrossRef PubMed
  27.Goldman D (2001) Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 44:995–998CrossRef PubMed
  28.Del Rosso JQ, Webster GF, Jackson M et al (2007) Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 56:791–802CrossRef PubMed
  29.Pfeffer I, Borelli C, Zierhut M et al (2011) Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 9:904–907PubMed
  30.Torresani C, Pavesi A, Manara GC (1997) Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 36:942–946CrossRef PubMed
  31.Schaller M, Sander CA, Plewig G (2003) Demodex abscesses: clinical and therapeutic challenges. J Am Acad Dermatol 49:S272–S274CrossRef PubMed
  32.Park H, Del Rosso JQ (2011) Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol 4:54–61PubMed PubMedCentral
  33.Gollnick H, Blume-Peytavi U, Szabo EL et al (2010) Systemic isotretinoin in the treatment of rosacea – doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 8:505–515PubMed
  34.Hsu CC, Lee JY (2012) Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. J Am Acad Dermatol 67:491–493CrossRef PubMed
  
• 作者单位：Dr. L.I. Gonser (1)
  Dr. C.E. Gonser (2)
  Prof. Dr. M. Schaller (1)
  
  1. Universitäts-Hautklinik Tübingen, 72076, Tübingen, Liebermeisterstraße 25, Deutschland
  2. BG Klinik Tübingen, Eberhard-Karls-Universität Tübingen, 72076, Tübingen, Schnarrenbergstraße 95, Deutschland
  
• 刊物主题：Dermatology; Immunology; Allergology; Proctology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-1173

文摘

Rosacea is a common chronic inflammatory disease, especially in patients with fair skin and positive family history. Typical locations are forehead, nose, cheeks and chin; the periorbital region is usually not involved. Clinical features can be very heterogeneous. Besides different subtypes (erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea), which often overlap, various special forms of rosacea exist. Up to 60 % of patients with cutaneous rosacea suffer from ocular rosacea. In Germany, brimonidine, metronidazol, azelaic acid, and ivermectin are approved for topical therapy of rosacea; for systemic therapy, doxycycline at a subantimicrobial dose (40 mg/day) is the only approved substance. In case of resistance to this therapy, contraindications or side effects, various alternative therapies are available, however off-label.